Compass Pathways (NASDAQ:CMPS) executives outlined plans for a potential U.S. regulatory filing and commercial launch preparation for its investigational psilocybin therapy, COMP360, during a recent ...
COMPASS Pathways plc (NASDAQ:CMPS) is given fourth position on our list of most promising stocks. TheFly reported on February 14 that LifeSci Capital was bullish on CMPS, as the firm initiated ...
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will attend the ...
COMPASS Pathways plc misses on earnings expectations. Reported EPS is $-0.38 EPS, expectations were $-0.37. Operator: Hello, everyone, and welcome to COMPASS Pathways Second Quarter 2025 Earnings ...
Investing.com - Compass Pathways (NASDAQ: CMPS) reported second quarter EPS of $-0.62, $0.09 better than the analyst estimate of ...
Good day, ladies and gentlemen, and welcome to this COMPASS Pathways update webinar. [Operator Instructions] As a reminder, this call is being recorded. I would now like to introduce your host for ...
COMPASS Pathways plc (NASDAQ:CMPS) is among the Best Get Rich Fast Stocks to Buy Right Now. As of December 24, COMPASS Pathways plc (NASDAQ:CMPS) has a ‘Buy’ or equivalent rating from the majority of ...
COMPASS Pathways plc misses on earnings expectations. Reported EPS is $-1.44451 EPS, expectations were $-0.4. Operator: Good morning, ladies and gentlemen, and thank you for standing by. My name is ...
Good morning, ladies and gentlemen, and thank you for standing by. My name is Kelvin, and I will be your conference operator today. At this time, I would like to welcome everyone to the COMPASS ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results